1.1.1 - GMP Regulatory Frameworks and Product Scope
0% read
GMP regulatory frameworks and product scope
Framework reference date: November 1, 2026, as specified in the course blueprint. Before investigating a deviation, establish which product, manufacturing activity, jurisdiction, and effective date define the applicable GMP framework.
What you will learn
Classify finished human drug products, active substances, biologics, human advanced therapy medicinal products, and veterinary medicinal products under GMP Regulatory Foundations: regulatory frameworks and product scope.
Select the appropriate FDA or EU framework for the actual manufacturing activity under GMP Regulatory Foundations: applicability assessment.
Distinguish binding requirements, adopted guidelines, final guidance, draft guidance, PIC/S standards, and voluntary practices under GMP Regulatory Foundations: source authority.
Document a defensible framework selection, including the supplied July 2026 EU veterinary transition, under GMP Regulatory Foundations: regulatory currency and evidence.
Blueprint mapping: GMP Regulatory Foundations → Regulatory Framework and Quality Governance → GMP Regulatory Frameworks and Product Scope. Blueprint reference: bp.d1.t1. Topic weight is not supplied.
EST. TIME 20–25 minutes. PREREQS None.
OUTPUTS You should be able to choose finished-product versus active-substance requirements, identify product-specific frameworks, and explain why a source applies before using it in a deviation record.
WHY
Why it matters
A well-written investigation can still be misdirected if it starts from the wrong product category or manufacturing stage.
Shared equipment, buildings, and quality procedures do not make every product subject to an identical regulatory framework.
The supplied blueprint identifies July 16, 2026 as the start of the separate EU veterinary GMP framework; an older reference list can therefore misdirect a current investigation.
A framework selection must connect an applicable source to the event being investigated, rather than merely collect familiar regulation numbers.
KEY TERMS
Key Terms & Must-Know Facts
GMP
Good manufacturing practice: requirements and expectations governing the consistent manufacture and control of medicinal products within an applicable framework.
CGMP
Current good manufacturing practice; the terminology used in the supplied FDA framework.
Finished drug product
The finished-product category distinguished here from manufacture of the active pharmaceutical ingredient.
Active pharmaceutical ingredient
An active substance; its manufacturing framework must be distinguished from the framework for the finished dosage product.
Biologic
A product category requiring assessment of applicable biologics-specific provisions in addition to relevant general requirements.
ATMP
Advanced therapy medicinal product; human ATMPs have a specific EU GMP framework in Volume 4 Part IV.
Product scope
The product category and intended human or veterinary use that help determine which framework applies.
Activity scope
The manufacturing or control operation under review, such as active-substance manufacture or finished-product packaging.
Binding requirement
An applicable legal obligation established through legislation or regulation; applicability still depends on scope and jurisdiction.
Regulatory guidance
A source explaining regulatory thinking or expectations; its status must be distinguished from the legal requirement it addresses.
Adopted guideline
A guideline brought into a regional regulatory framework through an adoption or implementation mechanism whose status must be established.
Effective date
The date on which a requirement or framework becomes applicable; publication date alone does not establish applicability.
Table 1. Product categories and framework starting points
Product or activity
Framework identified in the blueprint
Decision safeguard
US finished human drug product manufacture
21 CFR Parts 210 and 211
Assess the actual operation and applicable provisions.
Active pharmaceutical ingredient manufacture
ICH Q7; EU GMP Part II for EU active substances
Establish regional implementation rather than assuming identical legal status everywhere.
US biologics
Applicable provisions of 21 CFR Parts 600–680
Evaluate product-specific applicability alongside relevant general requirements.
EU finished human medicinal products
Directive 2001/83/EC; Directive (EU) 2017/1572; EudraLex Volume 4 Part I
Distinguish the legal framework from detailed GMP guidance.
EU human ATMPs
EudraLex Volume 4 Part IV
Do not substitute a generic Part I checklist without assessing the specific framework.
EU veterinary medicinal products from July 16, 2026
Implementing Regulations (EU) 2025/2091 and 2025/2154
Select the applicable instrument and provisions for the operation.
Must-know facts:
Product category and activity must be identified together.
The supplied source distinguishes finished-product requirements from active-substance GMP.
Biologics-specific requirements require an applicability assessment; a biologic label does not select every provision in Parts 600–680.
The supplied current EU human framework identifies Directive (EU) 2017/1572, rather than repealed Directive 2003/94/EC.
Part IV specifically addresses human ATMP GMP.
According to the blueprint, Volume 4 ceased to apply to veterinary medicinal products after July 15, 2026.
A draft, a final guidance document, and a regulation must not be described as having identical authority.
An unresolved classification should be escalated through the site quality system before a definitive regulatory conclusion is recorded.
CORE
Core content
1.1.1.1 1. Define product and activity before selecting a framework
A Explanation
Decision conflict: Choose the framework that fits the operation, or reuse the checklist that the site knows best. WHY THIS IS TESTED: Applicability errors can direct investigators toward irrelevant evidence while leaving the actual manufacturing obligation unexamined.
Start with four facts: what the product is, what operation occurred, which jurisdiction is relevant, and when the event occurred. A shared site name is insufficient. A company can manufacture an active substance at one stage and perform finished-product operations at another; the investigation should identify the stage implicated by the event.
Use the product description, manufacturing record, and controlled process documentation to establish the scope. Where classification is uncertain, record the uncertainty and seek the appropriate quality or regulatory input. Do not resolve it by choosing the most familiar acronym. See Fig 1.
Scope identification sequence Exam takeaway: Establish the operation before choosing its governing source.
Identify product category
Identify manufacturing stage
Identify jurisdiction and date
Select framework starting point
Confirm applicability
Fig 1. Framework selection begins with scope Exam takeaway: A familiar site procedure cannot replace product and activity classification.
flowchart TD; A[Identify event] --> B[Product category]; A --> C[Manufacturing activity]; B --> D[Jurisdiction and event date]; C --> D; D --> E[Applicable framework]; E --> F[Document selection rationale];
B Worked example
A site manufactures an active substance and also packages finished human tablets. The deviation concerns an active-substance drying operation intended for EU supply. An illustrative downstream patient is 67 years old with diabetes and chronic kidney disease; a potassium result of 5.2 mmol/L appears in an unrelated complaint attachment. The site recently passed a packaging audit using a Part I checklist.
Identify task: Select the framework for the drying-operation investigation. Extract key facts: Active-substance manufacture, EU supply, drying stage. Apply rule: Start with EU GMP Part II and the relevant active-substance expectations. Eliminate: The packaging audit concerns a different activity; the patient's conditions and potassium do not classify manufacturing scope. Verify: Confirm the material and operation in the batch and process records before finalizing the applicability statement.
C Exam trap
Wrong answer: Use the finished-product checklist because it is already approved for this building. Why tempting: A common site and an established checklist suggest consistency. Single eliminating clue: The event occurred during active-substance manufacture.
D Checkpoint MCQ
Which fact most directly selects the initial framework for a drying deviation at a mixed-operation site?
A. The department with the largest number of employees.
B. The classification of the material and the operation being performed.
C. The framework used in the site's most recent inspection.
D. The checklist preferred by the investigation owner.
Answer: B. A is tempting because department size suggests operational importance, but it does not establish scope. B is correct because product and activity determine the framework starting point. C is tempting because an inspection is authoritative, but its scope may differ from this event. D is tempting because familiarity improves speed, but preference does not establish applicability.
If you missed this: Review Define product and activity before selecting a framework — focus on the operation implicated by the event.
1.1.1.2 2. Separate legal obligation from guidance and practice
A Explanation
Decision conflict: Choose a source because of its verified authority and applicability, or treat every respected publication as an equivalent legal command. WHY THIS IS TESTED: Investigation conclusions and CAPA commitments must accurately describe what a source requires, recommends, or proposes.
First identify the issuing body, document type, status, and applicable region. Binding legislation and regulations establish obligations within their scope. Final guidance and adopted guidelines can support interpretation and implementation, but their status must be described accurately. An ICH guideline's title alone does not establish its legal effect in every jurisdiction. PIC/S standards support GMP alignment and inspection practice; determine their relationship to the applicable local framework rather than assigning them automatic legislative status.
Draft guidance signals a proposed approach. It must not be presented as an already applicable final requirement. Voluntary industry practices may be useful options, but they do not become legislation because they are widely used. Separately, an approved site procedure must be followed within the quality system; a voluntary external origin does not authorize staff to disregard the adopted procedure. See Fig 2.
Table 2. Source authority and appropriate use
Source type
Appropriate use
Unsupported shortcut to reject
Applicable legislation or regulation
Identify the binding obligation and its scope.
Assume a provision applies to every product made by the company.
Adopted ICH guideline or final guidance
Explain expectations while checking regional adoption and status.
Call every recommendation a universally binding statute.
Draft guidance
Track a proposed approach and assess potential future implications.
Treat publication as proof that a new final obligation is effective.
PIC/S standard
Support GMP alignment with attention to the applicable regulatory framework.
Assume membership or publication gives identical legal force everywhere.
Voluntary practice
Evaluate as a possible method within the quality system.
Present popularity as legal authority.
Source status sequence Exam takeaway: Read document status before converting text into an obligation.
Identify issuer
Classify document type
Confirm final or draft status
Check regional implementation
Describe authority precisely
Fig 2. Choose wording that matches source status Exam takeaway: A proposal, an interpretive source, and a binding requirement need different descriptions.
flowchart TD; A[Source under review] --> B{Document status}; B --> C[Applicable legislation or regulation]; B --> D[Final guidance or adopted guideline]; B --> E[Draft or voluntary practice]; C --> F[State scoped obligation]; D --> G[Explain status and implementation]; E --> H[Describe proposal or optional method];
B Worked example
A CAPA owner proposes a new reconciliation form after reading draft guidance. The product is used by an illustrative 59-year-old patient with hypertension and asthma; a normal sodium result is included in a complaint summary. The owner argues that the draft comes from a regulator and therefore requires the new form immediately.
Identify task: Decide how to justify the CAPA. Extract key facts: The cited document is a draft; the site has an existing approved reconciliation procedure. Apply rule: Evaluate the improvement against the actual requirement and site procedure, while describing the draft as a proposal. Eliminate: Regulator authorship does not remove draft status; patient history does not change document authority. Verify: Record the source version, current status, and quality-system approval for any resulting procedure change.
C Exam trap
Wrong answer: State that the new form is legally mandatory because a regulator published it. Why tempting: The issuing organization carries legitimate authority. Single eliminating clue: The cited document is explicitly marked draft.
D Checkpoint MCQ
A team wants to cite ICH Q7 as a binding requirement in every country. What is the most appropriate next step?
A. Confirm the applicable region's adoption and implementation status.
B. Replace the citation with an industry association checklist.
C. Accept the statement because ICH guidelines are internationally recognized.
D. Remove the guideline because it is not itself a national statute.
Answer: A. A is correct because adoption and implementation establish the relevant regional context. B is tempting because a checklist is operationally convenient, but it does not resolve authority. C is tempting because international recognition supports relevance, but it does not prove identical legal effect. D is tempting because the source is a guideline, but dismissing it ignores its potential adoption and regulatory significance.
If you missed this: Review Separate legal obligation from guidance and practice — focus on regional implementation rather than document prestige.
Quick Recall:
Complete: Product category plus manufacturing ______ identifies the framework starting point. Answer: activity.
True or false: A draft becomes a final requirement because its author is a regulator. Answer: False.
What additional check is needed for an adopted guideline? Answer: Its regional implementation and applicable status.
1.1.1.3 3. Apply category-specific FDA and EU frameworks
A Explanation
Decision conflict: Choose a category-specific framework, or assume that a general GMP reference covers every product without further assessment. WHY THIS IS TESTED: Broad labels such as drug, biologic, or medicinal product are not sufficient to select all applicable provisions.
For US finished human drug products, begin with 21 CFR Parts 210 and 211. For active-substance manufacture, distinguish ICH Q7 and its applicable regional implementation. For biologics, assess applicable provisions in Parts 600–680 alongside relevant general requirements; do not treat the product-specific range as a blanket replacement for all other requirements.
For EU human medicinal products, the supplied blueprint identifies Directive 2001/83/EC and Directive (EU) 2017/1572 as the legal framework. EudraLex Volume 4 provides detailed GMP guidance, including Part I for finished human medicinal products and Part II for active substances. Human ATMPs have a specific framework in Part IV. This lesson establishes selection principles; it does not supply every product-specific provision or resolve unusual classification questions.
The most appropriate next step for an ambiguous product is to confirm its classification with the relevant controlled documentation and qualified site functions. Do not infer ATMP status merely from a sterile presentation or a cold-storage requirement. See Fig 3.
Category-specific applicability sequence Exam takeaway: General and product-specific requirements must be assessed together.
Confirm product classification
Select jurisdiction
Select general framework
Assess specific framework
Record applicable provisions
Fig 3. EU human product framework comparison Exam takeaway: Finished products, active substances, and human ATMPs require distinct starting points.
flowchart TD; A[EU human product operation] --> B{Confirmed category}; B --> C[Finished medicinal product]; B --> D[Active substance]; B --> E[Human ATMP]; C --> F[Volume 4 Part I]; D --> G[Volume 4 Part II]; E --> H[Volume 4 Part IV];
B Worked example
A manufacturing team investigates a handling discrepancy for an EU product confirmed in its controlled documentation as a human ATMP. The illustrative intended recipient is 42 years old with diabetes and chronic pulmonary disease; a mildly elevated glucose result appears in the clinical packet. The team prefers its established Part I checklist because the product is supplied in a vial.
Identify task: Select the specific GMP framework. Extract key facts: EU jurisdiction and confirmed human ATMP classification. Apply rule: Start with Volume 4 Part IV and assess the relevant operation. Eliminate: Vial presentation does not override product classification; glucose does not determine regulatory scope. Verify: Connect the handling step to the applicable controlled requirements and document the basis for the selection.
C Exam trap
Wrong answer: Use Part I as the sole framework because the product is a finished medicinal product. Why tempting: The broad finished-product description appears to fit. Single eliminating clue: The product is specifically classified as a human ATMP.
D Checkpoint MCQ
A US biologic investigation cites Parts 600–680. Which statement best describes the next applicability check?
A. Select every provision in that range because the product is a biologic.
B. Evaluate relevant biologics-specific provisions alongside applicable general requirements.
C. Replace the biologics-specific review with an ICH Q7 checklist.
D. Use only the site's general finished-product procedure to establish legal scope.
Answer: B. A is tempting because the numbered range looks comprehensive, but individual provisions still require applicability assessment. B is correct because category-specific and relevant general requirements must be considered together. C is tempting because some operations involve active materials, but Q7 does not automatically replace biologics-specific review. D is tempting because approved procedures guide operations, but a site procedure alone does not establish the external framework.
If you missed this: Review Apply category-specific FDA and EU frameworks — focus on assessing specific requirements alongside relevant general requirements.
1.1.1.4 4. Control effective dates and document the applicability decision
A Explanation
Decision conflict: Choose the framework applicable to the event date, or keep using a historically correct reference after a transition. WHY THIS IS TESTED: A controlled document can be internally approved yet contain an outdated external reference.
The supplied blueprint states that EU veterinary medicinal products moved to the separate framework established by Implementing Regulations (EU) 2025/2091 and 2025/2154 from July 16, 2026, and that Volume 4 ceased to apply to veterinary medicinal products after July 15, 2026. Record the event date before deciding which framework governs the event. For a current operation, assess the current applicable veterinary instrument and provisions; do not treat the two instruments as interchangeable without examining their scopes.
A framework transition is not permission to stop containment, ignore a deviation, or make uncontrolled procedure changes. Record the event, preserve evidence, escalate the reference mismatch, and use the site's quality system to evaluate the effect on procedures, training, and any needed change control. The next lesson develops quality-unit decision rights; here, the investigator's task is to make the applicability basis visible and route unresolved questions appropriately.
A concise applicability statement identifies product category, operation, jurisdiction, event date, selected source and version, applicability rationale, and any unresolved scope question. A citation list without that reasoning is incomplete. See Fig 4 and Fig 5.
Date-controlled source selection Exam takeaway: A historical source must be evaluated against the event date and current operation.
Record event date
Check transition date
Select applicable source
Assess procedure mismatch
Document and escalate
Fig 4. EU veterinary framework date decision Exam takeaway: The supplied framework transition begins on July 16, 2026.
flowchart TD; A[EU veterinary event] --> B{Event date}; B --> C[Through July 15 2026]; B --> D[From July 16 2026]; C --> E[Assess historical applicable framework]; D --> F[Assess Regulations 2025/2091 and 2025/2154]; E --> G[Record dated rationale]; F --> G;
Fig 5. A usable applicability record Exam takeaway: A defensible selection connects source status to a specific operation.
flowchart TD; A[Product and operation] --> B[Jurisdiction and date]; B --> C[Source and version]; C --> D[Authority and scope]; D --> E[Applicability rationale]; E --> F[Open question and escalation if needed];
B Worked example
An EU veterinary product packaging deviation occurs on August 20, 2026. A training packet still cites Volume 4 as the governing veterinary framework. A separate product-use report describes a 10-year-old dog with diabetes and chronic kidney disease and includes a normal sodium result. The packaging line's strong inspection history is offered as a reason to keep the old reference.
Identify task: Choose the framework and address the reference mismatch. Extract key facts: Veterinary product, EU operation, event after July 15, 2026. Apply rule: Assess the separate veterinary framework and the relevant provisions in the named implementing regulations. Eliminate: Historical inspection success does not establish current applicability; the animal's conditions and sodium are not classification criteria for this decision. Verify: Document the selected source, escalate the outdated training reference, and evaluate controlled updates without bypassing existing deviation controls.
C Exam trap
Wrong answer: Continue citing Volume 4 because the procedure remains approved. Why tempting: Approval suggests that the procedure is authoritative and ready for use. Single eliminating clue: The veterinary event occurred after the supplied framework transition.
D Checkpoint MCQ
A controlled veterinary SOP contains an obsolete framework reference. What is the most appropriate response?
A. Close the deviation because the SOP was approved when issued.
B. Replace the reference informally and continue without documenting the mismatch.
C. Document the mismatch, assess applicable current requirements, and route controlled updates through the quality system.
D. Delay all event documentation until the external reference question is fully resolved.
Answer: C. A is tempting because approval demonstrates prior review, but it does not establish ongoing regulatory currency. B is tempting because the wording change appears simple, but informal replacement bypasses controlled assessment. C is correct because it addresses both applicability and document control. D is tempting because the team wants certainty, but uncertainty does not justify delaying the event record.
If you missed this: Review Control effective dates and document the applicability decision — focus on documenting and escalating a mismatch while maintaining event controls.
Quick Recall:
Which Volume 4 part specifically addresses human ATMPs? Answer: Part IV.
What date starts the separate veterinary framework in the supplied blueprint? Answer: July 16, 2026.
Does an approved SOP prove its external reference is still current? Answer: No; verify source status and effective date.
Choose a framework without delaying the event record Exam takeaway: Resolve applicability questions through the quality system while preserving the investigation record.
flowchart TD; A[Deviation recognized] --> B[Record facts and maintain containment]; B --> C{Framework clear}; C --> D[Document applicable source]; C --> E[Record uncertainty and escalate]; E --> F[Confirm scope and controlled updates]; D --> G[Continue evidence-based investigation]; F --> G;
Product scope sorting desk Exam takeaway: Product category and manufacturing activity are separate classification questions.
{"prompt":"Square clean educational vector illustration on white with blue gray and teal palette. A QA specialist sorts four clearly labeled cards: Finished human medicines, Active substances, Human ATMPs, Veterinary medicines. A separate checklist reads Product, Activity, Jurisdiction, Date. Keep labels inside generous margins. No agency logos or invented regulation numbers.","caption":"Product scope sorting desk","size":"1024x1024"}
One site, two manufacturing activities Exam takeaway: A common building does not make active-substance and finished-product operations equivalent.
{"prompt":"Square professional GMP training vector illustration, white background, blue gray and teal, generous margins. Two panels in one pharmaceutical site: left an enclosed active-substance dryer with a batch record labeled Active-substance operation; right a tablet packaging line labeled Finished-product packaging. A QA reviewer compares two separate scope checklists. No claims about equipment requirements and no agency logos.","caption":"One site, two manufacturing activities","size":"1024x1024"}
Document status review Exam takeaway: Verify document status before describing its authority.
{"prompt":"Square educational vector illustration of a quality reviewer examining four document covers labeled Regulation, Final guidance, Draft guidance, and Voluntary practice. Each has a visible status field and date field. Use equal-sized cards without a misleading legal hierarchy. White background, blue gray with teal accent, crisp outlines, generous margins, no official seals or logos.","caption":"Document status review","size":"1024x1024"}
EU human product framework comparison Exam takeaway: Confirmed human ATMP classification directs attention to Part IV.
{"prompt":"Square clean vector comparison illustration for pharmaceutical GMP training. Three equally sized panels: finished human medicine carton with a document labeled Part I; active-substance drum with document labeled Part II; human cell-therapy container with document labeled Part IV. Header EU human product categories. White background, blue gray and teal, all wording inside margins. No product-specific procedural instructions or agency logos.","caption":"EU human product framework comparison","size":"1024x1024"}
Veterinary framework transition review Exam takeaway: Event date determines which dated framework must be assessed.
{"prompt":"Square professional vector illustration of a veterinary pharmaceutical QA reviewer comparing two calendar cards labeled July 15 2026 and July 16 2026 beside a veterinary medicine carton. Under the second calendar a document reads Separate veterinary GMP framework. A legacy reference folder is clearly marked Historical reference. White background, blue gray teal palette, generous margins, no regulatory logos and no extra legal claims.","caption":"Veterinary framework transition review","size":"1024x1024"}
Applicability evidence review Exam takeaway: A source citation becomes useful when its relationship to the event is documented.
{"prompt":"Square GMP educational vector illustration showing a QA reviewer linking a batch record, a product classification sheet, an event-date card, and a source-status sheet to a central document labeled Applicability rationale. Include a small open-question box labeled Escalate if unresolved. White background, cool blue gray and teal, thin crisp lines, ample margins, no agency logos or invented requirements.","caption":"Applicability evidence review","size":"1024x1024"}
TRAPS
Exam Traps & Differentiators
Common traps & distractors:
Choose the strictest-looking source. Tempting because more requirements can appear safer; the eliminating clue is that the source addresses a different product or operation.
Treat an internal citation as proof of currency. Tempting because document approval signals control; the eliminating clue is an effective-date mismatch.
Classify by presentation. Tempting because vials, drums, or cold storage are visible; the eliminating clue is the product's confirmed regulatory classification.
Table 3. Similar-looking situations with different decisions
Looks similar
Discriminating fact
Appropriate decision
Active-substance drying versus finished-tablet packaging
Different manufacturing stages
Select the framework for the affected stage.
Ordinary finished human product versus human ATMP
Confirmed ATMP classification
Assess the specific Part IV framework.
Final guidance versus draft guidance
Document status
Distinguish current interpretation from a proposal.
Veterinary event before versus after the July 2026 transition
Event date
Use the dated applicable framework.
Approved SOP versus current external source
Different kinds of authority
Follow controlled event handling while assessing any reference mismatch.
If the scenario says:
Same site, different product stage → separate the activity scopes.
What is coming next: The supplied source pack does not identify a further proposed rule or future implementation date. Monitor controlled regulatory updates for changes in status, scope, and effective date. In the course sequence, Quality Unit Authority and Decision Rights develops who reviews, approves, or escalates the resulting quality decisions.
ALGO
Algorithm / Approach
Use this five-step approach when opening a deviation or checking an inspection narrative.
1. Classify: Identify human or veterinary use and the confirmed product category.
2. Locate: Identify the affected manufacturing or control activity and relevant jurisdiction.
3. Date: Record the event date and check applicable transition dates.
4. Evaluate: Select the source, confirm its status, and assess general plus product-specific applicability.
5. Record: State the rationale, retain source/version details, and escalate unresolved questions through the quality system.
Example applicability statement: The event concerns an EU active-substance drying operation. EU GMP Part II is the framework starting point because the affected operation is active-substance manufacture. The investigation record identifies the source version and event date; any additional product-specific question is routed to the appropriate site function.
QUIZ
Self-check quiz
Choose the most appropriate answer before reading the explanations.
1. A US finished human tablet packaging deviation occurs at a site that also manufactures active substances. Which framework is the most appropriate initial reference for the affected operation?
A. ICH Q7 because the company manufactures active substances.
B. 21 CFR Parts 210 and 211 for the finished-product operation.
C. 21 CFR Parts 600–680 because the operation is regulated by FDA.
D. EU GMP Part II because the facility has multiple manufacturing stages.
2. An EU product is confirmed to be a human ATMP. Which Volume 4 part is specifically identified for its GMP framework?
A. Part I.
B. Part II.
C. Part IV.
D. Part I selected solely because the product is supplied in final containers.
3. An EU veterinary packaging event occurs on September 2, 2026. Which action best addresses framework selection?
A. Use Volume 4 because it was cited in the previous inspection.
B. Assess the applicable provisions of Implementing Regulations (EU) 2025/2091 and 2025/2154.
C. Apply the human ATMP framework because it is product-specific.
D. Treat Directive (EU) 2017/1572 as the veterinary framework because it addresses GMP.
4. A draft guidance document recommends a new documentation method. Which statement is most defensible?
A. The method is legally mandatory because the document has a regulator as author.
B. The method cannot be considered until it appears in legislation.
C. The method may be evaluated as a proposed approach while current requirements and approved procedures remain the decision basis.
D. The method has the same status as final guidance because both explain regulatory thinking.
5. Which applicability record best supports an inspection narrative?
A. A list of familiar GMP sources without identifying the affected operation.
B. A statement that the site follows the most demanding available standard.
C. A copy of the SOP approval page without external source status.
D. Product category, operation, jurisdiction, event date, source/version, and a reasoned applicability statement.
ANSWERS
Answer key & explanations
1. Answer: B.
A: Tempting because the company does manufacture active substances; wrong because the affected operation is finished-product packaging.
B: Correct because Parts 210 and 211 are the supplied starting point for US finished human drug product operations.
C: Tempting because these are FDA regulations; wrong because regulator identity alone does not establish biologics-specific applicability.
D: Tempting because Part II addresses a manufacturing stage at the same facility; wrong because it does not match this US finished-product operation.
If you missed this: Review Define product and activity before selecting a framework — focus on the affected operation rather than the company's full portfolio.
2. Answer: C.
A: Tempting because Part I addresses finished human medicinal products; wrong because the supplied node identifies a specific human ATMP framework.
B: Tempting because advanced therapies involve active materials; wrong because Part II is the active-substance framework, not the selected human ATMP framework.
C: Correct because Part IV is specifically identified for human ATMP GMP.
D: Tempting because final containers suggest finished-product handling; wrong because presentation does not override confirmed classification.
If you missed this: Review Apply category-specific FDA and EU frameworks — focus on the specific framework selected by confirmed ATMP classification.
3. Answer: B.
A: Tempting because a prior inspection provides credible historical context; wrong because the event follows the supplied transition date.
B: Correct because the separate veterinary framework applies from July 16, 2026, with instrument-specific applicability still requiring assessment.
C: Tempting because a specific framework appears preferable to a broad one; wrong because human ATMP scope does not match a veterinary packaging event.
D: Tempting because the directive concerns GMP; wrong because the supplied blueprint identifies it within the human medicinal product framework.
If you missed this: Review Control effective dates and document the applicability decision — focus on the event date relative to July 16, 2026.
4. Answer: C.
A: Tempting because the issuing regulator has legitimate authority; wrong because authorship does not convert a draft recommendation into an effective legal requirement.
B: Tempting because it avoids overstating authority; wrong because a proposed method can still be evaluated through the quality system.
C: Correct because it preserves the distinction between a proposal and the current decision basis.
D: Tempting because both documents may discuss regulatory thinking; wrong because draft and final status must be distinguished.
If you missed this: Review Separate legal obligation from guidance and practice — focus on document status before assigning authority.
5. Answer: D.
A: Tempting because a broad bibliography appears thorough; wrong because it does not connect a source to this operation.
B: Tempting because conservative language suggests strong compliance; wrong because stringency does not establish applicability.
C: Tempting because approval demonstrates internal control; wrong because it does not establish current external source status or scope.
D: Correct because it makes the selection traceable and explains why the chosen framework governs the event.
If you missed this: Review Control effective dates and document the applicability decision — focus on a reasoned, event-specific applicability record.
RAPID
Rapid review / cheat-sheet
Scope ambiguity → obtain classification evidence before making a definitive regulatory conclusion.
Mixed-operation site → divide the investigation by affected activity when needed.
Guideline citation → explain regional implementation rather than assuming worldwide legal equivalence.
Biologics reference range → select applicable provisions rather than citing every provision.
Legacy procedure reference → assess both external currency and controlled internal updates.
Historical event → preserve the date-specific basis for the framework decision.
Inspection explanation → state why the source governs this event before describing compliance evidence.
Unresolved authority question → keep event documentation and evidence preservation moving through the quality system.
Key points
Select requirements using product, activity, jurisdiction, and date.
Describe source authority accurately.
Assess product-specific frameworks and effective-date transitions.
Document the applicability rationale and escalate unresolved questions.
Closing quick check: What fact would change your framework selection? Which source-status field would you verify before making a commitment? What evidence would let another reviewer reproduce your applicability decision?
End of your free lesson
Keep going with the full GMP Deviations, CAPA, and Inspection Readiness Professional Certificate
You just studied the way members do, in the same lesson interface. Full access unlocks every lesson, the question bank and flashcards for a full year.